Image Place holder

Brandon J. Blue, MD


Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Blue earned his MD at Meharry Medical College, Nashville, Tennessee. Dr. Blue completed an Internal Medicine Residency in the Department of Medicine at Washington University School of Medicine, St. Louis, Missouri, and d a Hematology/Oncology Fellowship in the Department of Medicine at Saint Louis University School of Medicine. Dr. Blue recently completed a Blood and Marrow Transplant and Cellular Immunotherapy Fellowship at Moffitt Cancer Center. Dr. Blue’s clinical interests include treatment of plasma cell disorders and evaluation of patients pre and post bone marrow transplant. His research interests include reducing health disparities and improving health outcomes for plasma cell dyscrasias.

Education & Training

Fellowship:

  • Moffitt Cancer Center - Blood and Marrow Transplant and Cellular Immunotherapy
  • Saint Louis University School of Medicine - Hematology/Oncology

Residency:

  • Washington University School of Medicine - Internal Medicine

Medical School:

  • Meharry Medical College - MD
Participating Trials

CLINICAL TRIAL 19194
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Not Applicable; bb21217; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19360
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM)
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Lenalidomide (Revlimid); carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19722
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Condition: Malignant Hematology
Intervention: bb2121; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18938
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19813
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (Karmma-3)
Condition: Malignant Hematology
Intervention: Bortezomib; CC-4047 (Pomalidomide); CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Ixazomib (Ninlaro); Lenalidomide (Revlimid); PS-341 (Bortezomib); Pomalidomide; Velcade (Bortezomib); bb2121; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 20038
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: CB-839; Dexamethasone; carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19093
Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: NY-ESO-1c259T; Pembrolizumab (Keytruda); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Blue B, Vegunta R, Rodin M, Patolia S, Poddar N. Impact of an Inpatient Palliative Care Consultation in Terminally Ill Cancer Patients. Cureus. 2018 Jul;10(7):e3016. Pubmedid: 30254805. Pmcid: PMC6150761.
  • Blue BJ, Luo S, Sanfilippo KM, Ganti A, Gumbel J, O'Brian K, Carson KR. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma. Brit J Haematol. 2017 Jan;176(2):322-324. Pubmedid: 26887893.
  • Sanfilippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, Gumbel J, Blue B, O'Brian K, Carson KR. Statins Are Associated With Reduced Mortality in Multiple Myeloma. J Clin Oncol. 2016 Nov;34(33):4008-4014. Pubmedid: 27646948. Pmcid: PMC5477827.